79 related articles for article (PubMed ID: 10098751)
1. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Terwogt JM; Mandjes IA; Sindermann H; Beijnen JH; ten Bokkel Huinink WW
Br J Cancer; 1999 Mar; 79(7-8):1158-61. PubMed ID: 10098751
[TBL] [Abstract][Full Text] [Related]
2. Miltefosine: new preparation. Solution for cutaneous application.
Prescrire Int; 1998 Feb; 7(33):5-6. PubMed ID: 10183390
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Smorenburg CH; Seynaeve C; Bontenbal M; Planting AS; Sindermann H; Verweij J
Anticancer Drugs; 2000 Nov; 11(10):825-8. PubMed ID: 11142690
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Leonard R; Hardy J; van Tienhoven G; Houston S; Simmonds P; David M; Mansi J
J Clin Oncol; 2001 Nov; 19(21):4150-9. PubMed ID: 11689583
[TBL] [Abstract][Full Text] [Related]
5. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
[TBL] [Abstract][Full Text] [Related]
7. 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers.
Eilender D; LoRusso P; Thomas L; McCormick C; Rodgers AH; Hooper CL; Tornyos K; Krementz ET; Parker S; Morgan LR
Cancer Chemother Pharmacol; 2006 Jun; 57(6):719-26. PubMed ID: 16184382
[TBL] [Abstract][Full Text] [Related]
8. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial.
Hartmann K; Siebenhaar F; Belloni B; Brockow K; Eben R; Hartmann B; Ruëff F; Schoepke N; Staubach P; Weber A; Maurer M
Br J Dermatol; 2010 Jan; 162(1):185-90. PubMed ID: 19785605
[TBL] [Abstract][Full Text] [Related]
9. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Clive S; Gardiner J; Leonard RC
Cancer Chemother Pharmacol; 1999; 44 Suppl():S29-30. PubMed ID: 10602908
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
[TBL] [Abstract][Full Text] [Related]
12. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Peukert M; Sindermann H; Hilgard P; Nagel G; Eibl H
Cancer Treat Rev; 1990 Sep; 17(2-3):243-6. PubMed ID: 2272039
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of topical ceramides for cutaneous breast cancer.
Jatoi A; Suman VJ; Schaefer P; Block M; Loprinzi C; Roche P; Garneau S; Morton R; Stella PJ; Alberts SR; Pittelkow M; Sloan J; Pagano R
Breast Cancer Res Treat; 2003 Jul; 80(1):99-104. PubMed ID: 12889603
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Mahieu-Renard L; Richard MA; Dales JP; Buscaylet S; Lagrassa S; Grob JJ
Ann Dermatol Venereol; 2005 Apr; 132(4):346-8. PubMed ID: 15886562
[TBL] [Abstract][Full Text] [Related]
15. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Bäumer W; Wlaź P; Jennings G; Rundfeldt C
Eur J Pharmacol; 2010 Feb; 628(1-3):226-32. PubMed ID: 19917276
[TBL] [Abstract][Full Text] [Related]
16. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: toxicity analysis of RTOG 95-17.
Kuske RR; Winter K; Arthur DW; Bolton J; Rabinovitch R; White J; Hanson W; Wilenzick RM
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):45-51. PubMed ID: 16503383
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
[TBL] [Abstract][Full Text] [Related]
19. [Early phase II study of MST-16 (sobuzoxane) for breast cancer].
Tominaga T; Shimozuma K; Hasegawa K; Hayashibara K; Nakahiro K; Nakao I; Katayama K; Fukuda M; Majima H; Aoyama H
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1009-15. PubMed ID: 8210250
[TBL] [Abstract][Full Text] [Related]
20. Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent.
Walochnik J; Obwaller A; Gruber F; Mildner M; Tschachler E; Suchomel M; Duchêne M; Auer H
J Antimicrob Chemother; 2009 Sep; 64(3):539-45. PubMed ID: 19549672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
